Neuronetics (STIM) Revenue & Revenue Breakdown
Neuronetics Revenue Highlights
Latest Revenue (Y)
$149.16M
Latest Revenue (Q)
$37.30M
Main Segment (Y)
Clinical Services Segment
Neuronetics Revenue by Period
Neuronetics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $149.16M | 99.17% |
| 2024-12-31 | $74.89M | 4.96% |
| 2023-12-31 | $71.35M | 9.42% |
| 2022-12-31 | $65.21M | 17.89% |
| 2021-12-31 | $55.31M | 12.32% |
| 2020-12-31 | $49.24M | -21.41% |
| 2019-12-31 | $62.66M | 18.72% |
| 2018-12-31 | $52.78M | 30.53% |
| 2017-12-31 | $40.43M | 18.13% |
| 2016-12-31 | $34.23M | - |
Neuronetics generated $149.16M in revenue during NA 2025, up 99.17% compared to the previous quarter, and up 302.89% compared to the same period a year ago.
Neuronetics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $37.30M | -2.13% |
| 2025-06-30 | $38.11M | 19.18% |
| 2025-03-31 | $31.98M | 42.16% |
| 2024-12-31 | $22.49M | 21.39% |
| 2024-09-30 | $18.53M | 12.64% |
| 2024-06-30 | $16.45M | -5.55% |
| 2024-03-31 | $17.42M | -14.26% |
| 2023-12-31 | $20.31M | 13.59% |
| 2023-09-30 | $17.88M | 1.56% |
| 2023-06-30 | $17.61M | 13.32% |
| 2023-03-31 | $15.54M | -14.61% |
| 2022-12-31 | $18.20M | 10.30% |
| 2022-09-30 | $16.50M | 1.03% |
| 2022-06-30 | $16.33M | 15.15% |
| 2022-03-31 | $14.18M | -5.60% |
| 2021-12-31 | $15.02M | 8.86% |
| 2021-09-30 | $13.80M | -2.84% |
| 2021-06-30 | $14.20M | 15.58% |
| 2021-03-31 | $12.29M | -21.12% |
| 2020-12-31 | $15.58M | 25.15% |
| 2020-09-30 | $12.45M | 27.79% |
| 2020-06-30 | $9.74M | -15.12% |
| 2020-03-31 | $11.48M | -33.88% |
| 2019-12-31 | $17.36M | 8.47% |
| 2019-09-30 | $16.00M | -3.45% |
| 2019-06-30 | $16.57M | 30.20% |
| 2019-03-31 | $12.73M | -18.59% |
| 2018-12-31 | $15.63M | 13.82% |
| 2018-09-30 | $13.74M | 3.66% |
| 2018-06-30 | $13.25M | 30.54% |
| 2018-03-31 | $10.15M | -16.15% |
| 2017-12-31 | $12.11M | 15.41% |
| 2017-09-30 | $10.49M | 1.78% |
| 2017-06-30 | $10.31M | 36.97% |
| 2017-03-31 | $7.53M | - |
Neuronetics generated $37.30M in revenue during Q3 2025, up -2.13% compared to the previous quarter, and up 226.73% compared to the same period a year ago.
Neuronetics Revenue Breakdown
Neuronetics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| Clinical Services Segment | $86.98M | - |
| Medical Device Segment | $62.18M | $74.89M |
Latest
Neuronetics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Clinical Services Segment (58.31%), and Medical Device Segment (41.69%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|---|
| Medical Device Segment | - | $37.30M | $1.22M | $31.98M |
Latest
Neuronetics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ATLN | Atlantic | $435.88M | $110.13M |
| STIM | Neuronetics | $149.16M | $37.30M |
| OSUR | OraSure | $115.02M | $1.75M |
| CDXS | Codexis | $70.39M | $8.60M |
| SGMO | Sangamo Therapeutics | $57.80M | $581.00K |
| GNFT | Genfit | $28.57M | $17.08M |
| PRE | Prenetics Global | $21.74M | $6.41M |
| OABI | OmniAb | $18.67M | $2.24M |
| PROF | Profound Medical | $16.10M | - |
| NYXH | Nyxoah | $4.30M | $1.22M |
| CATX | Perspective Therapeutics | - | $234.00K |